Results for chlorambucil translation from English to Slovenian

chlorambucil
klorambucil

chlorambucil n = 133
klorambucil n = 133

arzerra and chlorambucil (n=221)
arzerra in klorambucil (n = 221)

1see section 5.1 for information on chlorambucil dose
1 za podatke o odmerku klorambucila glejte poglavje 5.1.

arzerra given together with chlorambucil was compared with chlorambucil alone.
zdravilo arzerra v kombinaciji s klorambucilom so primerjali s samostojnim klorambucilom.

gazyvaro is used together with another medicine for cancer called chlorambucil.
zdravilo gazyvaro uporabljamo v kombinaciji z drugim zdravilom proti raku, imenovanim klorambucil.

data during follow up, especially for the chlorambucil alone arm, is limited.
podatkov iz obdobja spremljanja je malo, še zlasti za skupino, ki je dobivala samo klorambucil.

in patients who had not received treatment before, mabcampath was more effective than chlorambucil.
pri bolnikih, ki predhodno še niso bili zdravljeni, je bilo zdravilo mabcampath učinkovitejše od klorambucila.

for patients with cll the recommended dose of gazyvaro in combination with chlorambucil is shown in table 3.
za bolnike s kll priporočeni odmerek zdravila gazyvaro v kombinaciji s klorambucilom prikazuje preglednica 3.

the incidence of irrs was higher in the gazyvaro plus chlorambucil arm compared to the rituximab plus chlorambucil arm.
incidenca reakcij, povezanih z infuzijo, je bila večja s kombinacijo zdravila gazyvaro in klorambucila kot s kombinacijo rituksimaba in klorambucila.

the recommended dose of gazyvaro in combination with chlorambucil is 1,000 mg administered on day 1 of each cycle.
priporočeni odmerek zdravila gazyvaro v kombinaciji s klorambucilom je 1000 mg, uporabljen 1. dan vsakega ciklusa.

1 chlorambucil is given orally at 0.5 mg/kg body weight on day 1 and day 15 of all treatment cycles
1 klorambucil dajemo peroralno v odmerku 0,5 mg/kg telesne mase na 1. dan in 15. dan vseh ciklusov zdravljenja.

in addition, there were no apparent effects of bendamustine, fc, chlorambucil or chop on the pharmacokinetics of gazyvaro.
dodatno ni bilo vidnih učinkov bendamustina, fc, klorambucila ali chop na farmakokinetiko zdravila gazyvaro.

all grades gazyvaro + chlorambucil or gazyvaro +bendamustine (induction) followed by gazyvaro maintenance
vse stopnje zdravilo gazyvaro + klorambucil ali zdravilo gazyvaro + bendamustin (indukcija), sledi gazyvaro za vzdrževalno zdravljenje

co-administration with gazyvaro had no effect on the pharmacokinetics of bendamustine, fc, chlorambucil or the individual components of chop.
sočasno dajanje zdravila gazyvaro ni imelo vpliva na farmakokinetiko bendamustina, fc, klorambucila ali posameznih učinkovin v chop.

a total of 781 patients were randomized 2:2:1 to receive gazyvaro plus chlorambucil, rituximab plus chlorambucil or chlorambucil alone.
v celoti so 781 bolnikov v razmerju 2 : 2 : 1 randomizirali na prejemanje kombinacije zdravila gazyvaro in klorambucila, kombinacije rituksimaba in klorambucila ali samega klorambucila.

chlorambucil was given orally at 0.5 mg/kg body weight on day 1 and day 15 of all treatment cycles (1 to 6).
klorambucil so dobivali peroralno v odmerku 0,5 mg/kg telesne mase 1. in 15. dan v vseh ciklusih zdravljenja (od 1. do 6.).

nine patients treated with ofatumumab and chlorambucil, and three patients treated with chlorambucil alone had late onset neutropenia, defined as grade 3 or 4 neutropenia starting at least 42 days after the last treatment.
devet bolnikov, zdravljenih z ofatumumabom in klorambucilom, in trije bolniki, zdravljeni samo s klorambucilom, so imeli nevtropenijo s poznim nastankom, ki je opredeljena kot nevtropenija 3. ali 4. stopnje in se ne pojavi prej kot 42 dni po zadnjem zdravljenju.

mabcampath was shown to be superior to chlorambucil as measured by the primary endpoint progression free survival (pfs) (see figure 1).
izkazalo se je, da je zdravilo mabcampath boljše kot klorambucil, kar je razvidno iz meritev v prvi končni točki merjenja preživetja brez napredovanja bolezni (pfs) (oglejte si sliko 1).

at 6 months after the last dose, the median reductions in b cell counts were >99% for ofatumumab in combination with chlorambucil and 94% for chlorambucil alone.
Šest mesecev po zadnjem odmerku je bilo mediano zmanjšanje števila celic b pri kombinaciji ofatumumaba in klorambucila > 99 % in pri samem klorambucilu 94 %.